Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva UK has announced the patent expiry launch of Lercanidipine Hydrochloride film-coated tablets, available in 10mg and 20mg strengths in packs of 28.
Subscribe to our email newsletter
Lercanidipine Hydrochloride film-coated tablets are indicated for the treatment of mild to moderate, essential hypertension.
It is a generic version of Zanidip from Recordati and is available immediately in Teva 360 livery, which is designed to aid patient safety. Each tablet contains 10mg or 20mg lercanidipine hydrochloride.
Kim Innes, commercial director at Teva UK, said: “We are pleased to add this product to our ever expanding product portfolio.”
Teva Pharmaceutical specializes in the development, production and marketing of generic and proprietary branded pharmaceuticals, as well as active pharmaceutical ingredients.